Saudi Journal of Kidney Diseases and Transplantation (Jan 2020)

Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide

  • Umesh Lingaraj,
  • Kishan Aralapuram,
  • Sreedhara Chikkanayakanhalli,
  • Akila Vishwanathan,
  • Mahesha Vankalakunti

DOI
https://doi.org/10.4103/1319-2442.284029
Journal volume & issue
Vol. 31, no. 2
pp. 521 – 523

Abstract

Read online

Recurrence of glomerulonephritis is the third-leading cause of allograft loss. Graft loss due to IgA nephropathy occurs in 10% at 10-year follow-up. The NEFIGAN trial demonstrated that Target Release Formulation (TRF) of budesonide is a specific treatment for IgA nephropathy targeting intestinal mucosal immunity upstream of disease manifestation with favorable safety profile. We are reporting a case of successful treatment of a patient with posttransplant IgA nephropathy with TRF of budesonide.